Using FDG-PET to Guide Hodgkin Lymphoma Treatment

Video
Conference|American Society of Hematology Annual Meeting & Exposition (ASH)

This interview examines the role of functional imaging to direct therapy (escalation or de-escalation) for early and advanced Hodgkin lymphoma.

In this interview, Peter Johnson, MD, of the University of Southampton in the United Kingdom, discusses the results of trials testing the role of FDG–positron emission tomography (PET) to direct therapy (escalation or de-escalation) for patients with both early and advanced Hodgkin lymphoma.

Dr. Johnson spoke at an education session on how Hodgkin lymphoma is treated today and the challenges ahead at the 58th Annual Meeting of the American Society of Hematology, held December 3–6 in San Diego, California.

Related Videos
Resolving disparities within the blood cancer space is a matter of “access to excellent healthcare,” according to Usama Gergis, MD, MBA.
Discrepancies in patients with blood cancer who are eligible for but do not undergo hematopoietic stem cell transplant have been observed not only for Black patients, but Hispanic, Asian, and White patients as well, according to Usama Gergis, MD, MBA.
Expert on myelofibrosis
Expert on myelofibrosis
Experts on myelofibrosis
Expert on myelofibrosis
Expert on myelofibrosis
Expert on myelofibrosis
Related Content
FDA Warns BCMA-, CD19-Directed Autologous CAR T-Cell Therapy May Lead to T-Cell Malignancies

FDA Warns BCMA-, CD19-Directed Autologous CAR T-Cell Therapy May Lead to T-Cell Malignancies

November 29th 2023
Article

Six BCMA-directed, CD19-directed autologous CAR T-cell therapies are under investigation for the potential risk of T-cell malignancies.

Oncology Peer Review On-The-Go: Minority Treatment Disparities and Clinical Trial Enrollment

Oncology Peer Review On-The-Go: Minority Treatment Disparities and Clinical Trial Enrollment

July 6th 2020
Podcast

The first episode of CancerNetwork's podcast Oncology Peer Review On-The-Go explores disparities in cancer care treatment among minorities and the significance of a representative sample in clinical trials.

Impact of GVHD Prophylaxis on CMV Reactivation and Disease After HLA-matched Peripheral Blood Stem Cell Transplantation

Impact of GVHD Prophylaxis on CMV Reactivation and Disease After HLA-matched Peripheral Blood Stem Cell Transplantation

November 22nd 2023
Article

A recent study published in Nucleus highlighted the impact of graft-vs-host disease prophylaxis on cytomegalovirus reactivation.

Stem Cell Transplant Approaches for Patients With Blood Cancers

Stem Cell Transplant Approaches for Patients With Blood Cancers

March 13th 2019
Podcast

Dr. Scadden discusses which blood cancer patients are eligible for stem cell transplantation, as well as the latest advances in the field.

Data from the phase 3 ECHELON-1 trial support the European Commission’s approval of brentuximab vedotin plus chemotherapy as a treatment for those with CD30-positive stage III Hodgkin lymphoma.

Brentuximab Vedotin Combo Earns European Approval in Hodgkin Lymphoma

October 19th 2023
Article

Data from the phase 3 ECHELON-1 trial support the European Commission’s approval of brentuximab vedotin plus chemotherapy as a treatment for those with CD30-positive stage III Hodgkin lymphoma.

Selecting and Sequencing Ruxolitinib, Other Treatments in Chronic GVHD

Selecting and Sequencing Ruxolitinib, Other Treatments in Chronic GVHD

October 14th 2023
Article

Nelson J. Chao, MD, MBA, and his colleagues discussed the use of ruxolitinib as treatment for patients with graft-vs-host disease.